Virnetx (NASDAQ:VHC – Get Free Report) and Avalon GloboCare (NASDAQ:CHGA – Get Free Report) are both small-cap technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.
Analyst Ratings
This is a summary of current ratings and recommmendations for Virnetx and Avalon GloboCare, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Virnetx | 1 | 0 | 0 | 0 | 1.00 |
| Avalon GloboCare | 1 | 0 | 0 | 0 | 1.00 |
Institutional and Insider Ownership
10.4% of Virnetx shares are held by institutional investors. Comparatively, 1.4% of Avalon GloboCare shares are held by institutional investors. 15.7% of Virnetx shares are held by insiders. Comparatively, 16.8% of Avalon GloboCare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility & Risk
Profitability
This table compares Virnetx and Avalon GloboCare’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Virnetx | N/A | -92.46% | -66.74% |
| Avalon GloboCare | N/A | N/A | -53.69% |
Valuation & Earnings
This table compares Virnetx and Avalon GloboCare”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Virnetx | $160,000.00 | 286.39 | -$18.23 million | ($5.37) | -2.03 |
| Avalon GloboCare | $1.26 million | 1.50 | -$18.26 million | ($13.80) | -0.12 |
Virnetx has higher earnings, but lower revenue than Avalon GloboCare. Virnetx is trading at a lower price-to-earnings ratio than Avalon GloboCare, indicating that it is currently the more affordable of the two stocks.
Summary
Virnetx beats Avalon GloboCare on 5 of the 9 factors compared between the two stocks.
About Virnetx
VirnetX Holding Corporation, through its subsidiary VirnetX, Inc., operates as an Internet security software and technology company primarily in the United States. The company develops software and technology solutions, including secure domain name registry and GABRIEL Connection Technology that are designed to secure communications over the Internet using zero trust network access. It also offers a portfolio of licenses and services, such as VirnetX One, a security-as-a-service platform that protects enterprise applications, services, and infrastructure from cyber-attacks; GABRIEL Connection Technology software development kit to assist with rapid integration of its techniques into existing software implementations; and War Room software that offers safe and secure video conferencing meeting environment where sensitive communications and data is invisible to those not authorized to view it. In addition, the company provides GABRIEL Collaboration Suite that enables seamless and secure cross-platform communications between users’ devices. It serves domain infrastructure and communication service providers, and system integrators; and enterprise customers, developers, and original equipment manufacturers of chips, servers, desktops, smart phones, tablets, laptops, net books, and other devices in the IP-telephony, mobility, fixed-mobile convergence, and unified communications markets. The company was incorporated in 2005 and is headquartered in Zephyr Cove, Nevada.
About Avalon GloboCare
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.
Receive News & Ratings for Virnetx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virnetx and related companies with MarketBeat.com's FREE daily email newsletter.
